Originally developed for treating pulmonary hypertension, riociguat enhances cardiopulmonary hemodynamics by stimulating soluble guanylate cyclase (sGC) activity, drawing parallels with the third-ranked term guanylate (inclusion due to its anti-hypertensive drug prefix “guan-”), which is also the main target of riociguat. The gene discussed is SGCB; the disease is pulmonary arterial hypertension.